Penetration and exposure of cefotiam into the peritoneal fluid of abdominal surgery patients after intravenous administration

Journal of Chemotherapy

Volumn 20, Issue 3, 2008, Pages 319-323

  Ikawa, K ^a   Morikawa, N ^a   Fukuhara, K ^a   Hayato, S ^a   Ikeda, K ^a   Soga, Y ^a   Ohge, H ^a   Sueda, T ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cefotiam; Peritoneal fluid; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFOTIAM;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; BLOOD SAMPLING; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG PENETRATION; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA; MALE; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL FLUID; PREOPERATIVE PERIOD; SIMULATION; STOCHASTIC MODEL; SURGICAL PATIENT; VENOUS BLOOD;

EID: 47349126660     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.3.319     Document Type: Article

References (13)

1. Ikawa K, Morikawa N, Hayato S, Ikeda K, Ohge H, Sueda T. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents 2007; 30: 270-3.
2. Ikawa K, Morikawa N, Matsuda S, et al. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients. Int J Antimicrob Agents 2007; 30: 352-5.
3. Dao C, Hercelin B, Chotard Y, Veil N. Diffusion of cefotiam into ascitic fluid. Pathol Biol 1985; 33: 527-9.
4. Latrive JP, Barbare JC, Darchis JP, Hercelin B, Rosembaum M. Course of the diffusion of cefotiam in infected ascitic fluid. Pathol Biol 1987; 35: 707-10.
5. Miglioli PA, Schoeffel U, Gabroska E, Allerberger F. Anti-bacterial activity of peritoneal exudate in patients treated with 2 g cefotiam for surgical anti-microbial prophylaxis. Chemotherapy 1998; 44: 149-52.
6. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
7. Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 2005; 56: 893-8.
8. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45: 13-22.
9. Kees F, Raasch W, Steger M, Grobecker H. High-performance liquid chromatographic assay for cefotiam and d3-cefotiam in human serum. J Chromatogr 1990; 525: 484-9.
10. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Phar-macobiodyn 1981; 4: 879-85.
11. Shinagawa N, Hirata K, Katsuramaki T, et al. Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - special references to bacteria isolated between April 2004 and March 2005. Jpn J Antibiot 2006; 59: 72-116.
12. Shinagawa N, Mizuno I, Hirata K, et al. Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - special references to bacteria isolated between April 2005 and March 2006. Jpn J Antibiot 2007; 60: 59-97.
13. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205-10.